While the<unk> <unk> ytic adenovirus has shown efficacy as a single agent against several soft tissue sarcomas, it would also be appealing to use in combination with other regimes, as<unk> ytic viruses have demonstrated very little overlap in side effects with traditional therapies such as chemotherapy and radiation.<unk>  has recently been studied in combination with doxorubicin, and a synergistic effect was observed. At least part of doxorubicin's mechanism of action is as an inducer of immunogenic cell death, and it has been suggested that immune response contributes to its overall anti-tumor activity. Doxorubicin has been shown to increase adenoviral replication in soft tissue sarcoma cells as well, potentially contributing to the observed synergistic effect in the virus/doxorubicin combination. While in phase I was already used to treat 200 advanced cancer patients in the company's Advanced Therapy Access Program.
ONCOS-102
CARB-X
MCN
SCALPEL
BGR-34
BIM-1
COVAX-19
CURB-65